Literature DB >> 25478177

Regional variations in the prevalence and misdiagnosis of air flow obstruction in China: baseline results from a prospective cohort of the China Kadoorie Biobank (CKB).

Om P Kurmi1, Liming Li1, Margaret Smith1, Mareli Augustyn1, Junshi Chen1, Rory Collins1, Yu Guo1, Yabin Han1, Jingxin Qin1, Guanqun Xu7, Jian Wang8, Zheng Bian1, Gang Zhou1, Kourtney Davis10, Richard Peto1, Zhenming Chen1, Liming Li1, Zhengming Chen1, Junshi Chen1, Rory Collins1, Richard Peto1, Zhengming Chen1, Garry Lancaster1, Xiaoming Yang1, Alex Williams1, Margaret Smith1, Ling Yang1, Yumei Chang1, Iona Millwood1, Yiping Chen1, Sarah Lewington1, Sam Sansome1, Robin Walters1, Om Kurmi1, Yu Guo1, Zheng Bian1, Can Hou1, Yunlong Tan1, Zheng Wang1, Xin Cai1, Huiyan Zhou1, Xuguan Chen1, Zengchang Pang1, Shanpeng Li1, Shaojie Wang1, Silu Lv1, Zhonghou Zhao1, Shumei Liu1, Zhigang Pang1, Liqiu Yang1, Hui He1, Bo Yu1, Shanqing Wang1, Hongmei Wang1, Chunxing Chen1, Xiangyang Zheng1, Xiaoshu Hu1, Minghao Zhou1, Ming Wu1, Ran Tao1, Yeyuan Wang1, Yihe Hu1, Liangcai Ma1, Renxian Zhou1, Zhenzhu Tang1, Naying Chen1, Ying Huang1, Mingqiang Li1, Zhigao Gan1, Jinhuai Meng1, Jingxin Qin1, Xianping Wu1, Ningmei Zhang1, Guojin Luo1, Xiangsan Que1, Xiaofang Chen1, Pengfei Ge1, Xiaolan Ren1, Caixia Dong1, Hui Zhang1, Enke Mao1, Zhongxiao Li1, Gang Zhou1, Shixian Feng1, Yulian Gao1, Tianyou He1, Li Jiang1, Huarong Sun1, Min Yu1, Danting Su1, Feng Lu1, Yijian Qian1, Kunxiang Shi1, Yabin Han1, Lingli Chen1, Guangchun Li1, Huilin Liu1, Li Yin1, Youping Xiong1, Zhongwen Tan1, Weifang Jia1.   

Abstract

BACKGROUND: Despite the great burden of chronic respiratory diseases in China, few large multicentre, spirometry-based studies have examined its prevalence, rate of underdiagnosis regionally or the relevance of socioeconomic and lifestyle factors.
METHODS: We analysed data from 512 891 adults in the China Kadoorie Biobank, recruited from 10 diverse regions of China during 2004-2008. Air flow obstruction (AFO) was defined by the lower limit of normal criteria based on spirometry-measured lung function. The prevalence of AFO was analysed by region, age, socioeconomic status, body mass index (BMI) and smoking history and compared with the prevalence of self-reported physician-diagnosed chronic bronchitis or emphysema (CB/E) and its symptoms.
FINDINGS: The prevalence of AFO was 7.3% in men (range 2.5-18.2%) and 6.4% in women (1.5-18.5%). Higher prevalence of AFO was associated with older age (p<0.0001), lower income (p<0.0001), poor education (p<0.001), living in rural regions (p<0.001), those who started smoking before the age of 20 years (p<0.001) and low BMI (p<0.001). Compared with self-reported diagnosis of CB/E, 88.8% of AFO was underdiagnosed; underdiagnosis proportion was highest in 30-39-year olds (96.7%) compared with the 70+ age group (81.1%), in women (90.7%), in urban areas (89.4%), in people earning 5K-10 K ¥ monthly (90.3%) and in those with middle or high school education (92.6%).
INTERPRETATION: In China, the burden of AFO based on spirometry was high and significantly greater than that estimated based on self-reported physician-diagnosed CB/E, especially in rural areas, reflecting major issues with diagnosis of AFO that will impact disease treatment and management.

Entities:  

Keywords:  COPD Epidemiology; Tobacco and the Lung

Year:  2014        PMID: 25478177      PMCID: PMC4212802          DOI: 10.1136/bmjresp-2014-000025

Source DB:  PubMed          Journal:  BMJ Open Respir Res        ISSN: 2052-4439


This is the largest population-based multi-centre study of prevalence and socioeconomic and lifestyles correlates of air flow obstruction (AFO) representative of adult Chinese population selected from ten diverse regions of China. The data suggests up to 10-fold difference in prevalence of AFO between different regions in China for both men and women. The result highlights that mis-diagnosis of AFO (>80%) in Chinese population is a major issue requiring immediate attention to improve both appropriate management and prevention programs.

Introduction

Globally, chronic obstructive pulmonary disease (COPD) is responsible for about three million annual deaths, and for an even greater burden from disability,1 with particularly high-disease prevalence in low-income and middle-income countries such as China where smoking prevalence is very high among men.2 In China, over 90% of 1.4 million respiratory-related deaths3 and 10.4 million disability-adjusted life years4 are attributed to COPD in adults, with most of the COPD-related deaths occurring at the age of 60 years or older.4 Among published epidemiological studies conducted in China, there are large unexplained variations in the age-specific rates of COPD between men and women and between different regions, with reported prevalence ranging from 3% to 12% in ages above 40 years.5–7 Smoking is a major risk factor for COPD but few women in China smoke (<5%), so this exposure cannot explain the relatively high prevalence of COPD seen in many parts of China.8 There is also evidence that exposure to environmental air pollutants particularly coal and wood smoke for cooking and heating, low socioeconomic status and lung infections such as tuberculosis earlier in life may contribute to increased risk of COPD, but the evidence is still extremely limited in China.5 As well as risk exposures, difference in survey methods and COPD diagnosis methods between different studies could also affect the burden of the disease estimated for different populations. There is good evidence that defining COPD based only on self-reported physician-diagnosis tends to significantly underestimate the true burden, particularly in resource-poor areas where access to healthcare is limited and also possibly due to lack of awareness of their condition.9 Despite this, most of the previous studies in China tended to use self-reported information rather than spirometry-defined COPD. Consequently, substantial uncertainty remains about the true burden of COPD in the population. To help fill the gap in knowledge, we analysed the cross-sectional data of the China Kadoorie Biobank (CKB) of over 0.5 million adults from 10 diverse regions of China.10 The aims of the study were (1) to estimate the prevalence of air flow obstruction (AFO) based on the measured lung function and its variation with socioeconomic and lifestyle factors, (2) to examine the prevalence of self-reported physician-diagnosed chronic bronchitis/emphysema (CB/E), rates of treatment and (3) to assess the proportion of underdiagnosis by comparing the prevalence of AFO based on spirometry with self-reported physician-diagnosed CB/E and any variation with socioeconomic and lifestyle factors.

Methods

Study design and participants

A detailed description of the study design, survey methods and characteristics of participants for the CKB prospective study is published elsewhere.8 10 In brief, the baseline survey took place between 2004 and 2008 involving five rural and five urban regions, chosen according to local disease patterns, exposure to certain risk factors, population stability, quality of death and diseases registries, local commitment and capacity. Overall, a total of 512 891 adults (210 222 men and 302 669 women) aged 30–79 were enrolled. All participants gave informed written consent.

Data collection

Laptop-based questionnaire was administered to each participant by trained health workers, who collected detailed information on demographic and socioeconomic status, dietary and other lifestyle factors (eg, smoking, alcohol use), exposure to passive smoking and household air pollution, respiratory symptoms (eg, chronic cough, production of chronic phlegm, breathlessness and severity of breathlessness), medical history of physician-diagnosed respiratory (chronic bronchitis, emphysema, asthma, tuberculosis) and other conditions (eg, stroke, ischaemic heart disease, cancer and diabetes), physical activity, sleeping and mental status and reproductive history (for women) at baseline. A range of physical measurements was taken, including standing and sitting height, weight, bioimpedance, exhaled carbon-monoxide and blood pressure.

Spirometry and diagnostic criteria for AFO

Spirometry was carried out by trained health technicians, using portable handheld ‘Micro spirometer’ (Micro Medical Limited, Rochester, Kent, England) in accordance with modified American Thoracic Society (ATS)11 procedures developed by our respiratory team. The spirometer we used during the baseline survey did not display flow volume loops, and hence the acceptability criterion of blows was modified. Participants made some practice blows, after which the results of two successful manoeuvres (as judged by the technician) were recorded for each participant. The larger of the two forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were used for calculating FEV1/FVC ratio and for further analysis. No bronchodilators were used at the baseline survey. Overall, 202 men and 194 women with an FEV1/FVC >1 were excluded, leaving 210 020 (99.9%) men and 302 475 (99.9%) women for the present analysis. For the present analysis, AFO is defined according to the lower limit of normal (LLN) definition as FEV1/FVC We defined chronic bronchitis as the presence of cough and phlegm for more than 3 months in the past 12 months. Underdiagnosis was defined as participants with AFO defined by spirometry but not physician-diagnosed CB/E and overdiagnosis was defined as those participants with physician-diagnosed CB/E but not AFO defined by spirometry.

Statistical methods

All analyses were conducted separately for men and women. Baseline demographic characteristics were calculated by rural/urban area, and crude prevalence of AFO was calculated by region and urban/rural area. The prevalence of AFO (directly standardised to the study population male or female 5-year age group structure) was calculated for each region. Further, AFO prevalence for strata of various potential risk factors or correlates within urban and rural areas was calculated (directly standardised to the study population 10-year age group and region structure, as necessary). Similarly, we also calculated age and region-standardised prevalence of a number of chronic health conditions among those with AFO. Association between participants’ characteristics and AFO diagnosis type was carried out using multivariate logistic regression. All statistical analyses were performed using SAS V.9.3.

Results

At baseline, the overall mean age of participants was 52.0±10.7 years, 59% were women and 56% were from rural areas (table 1). The proportion of participants having at least 6 years of formal education was higher in urban compared with rural areas and higher in men than in women. The prevalence of ever regular smoking was significantly higher among men than women (74.3% vs 3.2%) and somewhat higher in rural than in urban men (77.7% vs 70.1%). The proportion reporting current use of clean fuel (ie, gas or electricity for cooking) was much higher in urban than in rural areas for men (56.5% vs 7.1%) and women (83.6% vs 12.4%). The mean body mass index (BMI) was lower in rural than in urban areas for men (24.3 vs 22.7 kg/m2) and women (24.3 vs 23.5 kg/m2), with approximately 5–6% of rural participants classified as underweight (BMI <18.5 kg/m2) compared with around 3% of urban participants (table 1).
Table 1

Baseline characteristics of participants by sex and region types (figures in the column are % of total)

CharacteristicsMen
Women
Rural (%)N=118 837Urban (%)N=91 220Rural (%)N=167 727Urban (%)N=134 711
Height (mean±SD in cm)164.1±6.3166.8±6.5153.2±5.9155.3±5.9
Age (years)
 30–3914.513.518.213.1
 40–4927.728.831.430.2
 50–5931.229.131.230.7
 60–6919.819.515.018.8
 70–796.89.14.27.2
 Mean (SE)52.6 (0.03)53.1 (0.04)50.5 (0.02)52.6 (0.03)
BMI (kg/m2)
 <18.55.72.85.23.2
 18.5 to <2571.555.364.357.9
 ≥2522.741.830.538.9
 Mean (SE)22.7 (0.01)24.3 (0.01)23.5 (0.01)24.3 (0.01)
Smoking status
 Never smoker11.318.494.495.5
 Occasional smoker11.011.52.01.6
 Ex-regular smoker11.815.30.90.8
 Current regular smoker65.954.82.62.1
Pack years*
 <1019.719.347.751.7
 10–2023.126.326.525.1
 >2057.154.525.823.2
 Mean (SE)26.7 (0.07)24.8 (0.07)15.2 (0.2)13.7 (0.22)
Age started smoking (years)
 <2034.733.135.121.9
 20–2438.036.621.416.6
 25–2912.515.812.212.4
 ≥3014.814.631.449.1
Number of cigarettes smoked daily (or equivalent)
 1–47.24.729.124.9
 5–1427.530.847.251.3
 15–2445.147.820.420.7
 ≥2520.216.73.33.1
Reason for stopping among ex-smokers
 Physical illness53.245.964.140.8
 Other reason46.854.135.959.2
Exposure to passive smoking†73.763.087.583.2
 Highest education completed
  No formal education12.74.031.717.3
  Primary school43.819.740.420.3
  Middle or high school41.860.527.253.3
  College or university1.715.90.69.2
Household income (yuan/year)
 2500–499914.32.615.14.1
 5000–999923.58.026.111.5
 10 000–19 99928.927.628.930.4
 ≥20 00033.361.729.954.1
Exposure to cooking fuels‡
 Currently cooks with coal/wood27.75.381.08.7
 Ever cooked with coal/wood32.733.692.661.0
 Currently cooks with gas/electricity7.156.512.483.6
Respiratory symptoms
 Chronic cough and phlegm7.36.22.61.8
 Breathlessness5.83.48.54.7

*Restricted to ever regular smokers.

†Defined as never smokers who lived with a smoker or were exposed at work for 1–5 days/week or daily.

‡Restricted to participants who reported cooking daily or weekly.

BMI, body mass index.

Baseline characteristics of participants by sex and region types (figures in the column are % of total) *Restricted to ever regular smokers. †Defined as never smokers who lived with a smoker or were exposed at work for 1–5 days/week or daily. ‡Restricted to participants who reported cooking daily or weekly. BMI, body mass index. The lung function indices (FEV1, FVC and FEV1/FVC) decreased steeply with increasing age (see online supplementary figures S1–S3) and were lower in rural than urban areas for men and women at all age groups (data not shown). Among women and men, ever smokers had higher FEV1 until the mid-40s; whereas FVC continued to be higher until the 50s, but then FEV1 and FVC decreased steeply with increasing age and were lower in ever smokers compared with never smokers. Overall at baseline, 4.1% reported having chronic cough and phlegm, which was higher in rural than in urban areas for men (7.3% vs 6.2%, p<0.001) and women (2.6% vs 1.8%, p<0.001). Similar rural and urban differences were seen for breathlessness while walking on level ground for men (5.8% vs 3.4%, p<0.001) and women (8.5% vs 4.7%, p<0.001), but the reported prevalence was higher in women (table 2).
Table 2

Participant characteristics relating to AFO, by region and sex (figures are in percentage of total unless stated)

Men
Women
RuralUrbanOverallRuralUrbanOverall
Total118 83791 220210 057167 727134 711302 438
Mean age (years)52.653.152.950.552.651.5
AFO GOLD stage I–IV8.44.56.75.53.34.4
AFO GOLD stage II–IV7.03.65.54.62.43.5
AFO LLN9.24.87.37.74.86.3
Classification of severity of AFO (values are % predicted)*
Mild (FEV1 ≥80%)1.40.91.20.90.91.4
Moderate (50% ≤ FEV1 ≥80%)4.22.43.42.91.74.2
Severe (50% ≤ FEV1 ≥80%)2.21.01.61.40.62.2
Very severe (FEV1 <80%)0.70.30.50.30.10.7
Doctor diagnosed CB/E3.22.93.12.12.42.2
Doctor diagnosed CB/E and still on treatment34.828.432.137.827.432.7
Doctor diagnosed CB/E and
 AFO GOLD stage I–IV†40.522.833.131.514.323.0
 AFO GOLD stage II–IV†39.621.732.230.412.921.7
 AFO LLN†39.522.032.335.616.726.3
Under diagnosis86.186.686.290.391.590.7
Over diagnosis60.578.067.764.483.373.7
Doctor diagnosed asthma0.40.80.60.30.80.5
Breathlessness‡5.83.44.78.54.76.8
Chronic cough§6.84.55.83.01.82.4
Chronic cough and sputum¶7.36.26.82.61.82.2
Chronic cough with sputum and
 AFO GOLD stage I–IV**17.39.814.417.58.414.1
 AFO GOLD stage II–IV**15.88.613.115.87.212.7
 AFO LLN**18.910.115.520.810.016.9

p Value for difference between urban and rural <0.0001 except men: doctor-diagnosed CB/E (p=0.0002); underdiagnosis (p=0.3775) women: underdiagnosis (p=0.0032).

*Based on prebronchodilator FEV1 in participants with FEV1/FVC <0.70 according to modified GOLD definition.

†Figures are percentage of different GOLD stages of AFO or LLN based AFO in those with doctor diagnosed CB/E.

‡Becomes short of breath while walking on level ground with healthy people of same age.

§Had cough for at least 3 months in the past 12 months.

¶Cough up sputum in the morning for at least 3 months in the past 12 months.

**Figures are percentage of different GOLD stages of AFO or LLN based AFO in those with chronic cough and sputum.

AFO, air flow obstruction; CB/E, chronic bronchitis/emphysema; FEV1, forced expiratory volume in 1 s; GOLD, Global Initiative for Obstructive Lung Disease; LLN, lower limit of normal.

Participant characteristics relating to AFO, by region and sex (figures are in percentage of total unless stated) p Value for difference between urban and rural <0.0001 except men: doctor-diagnosed CB/E (p=0.0002); underdiagnosis (p=0.3775) women: underdiagnosis (p=0.0032). *Based on prebronchodilator FEV1 in participants with FEV1/FVC <0.70 according to modified GOLD definition. †Figures are percentage of different GOLD stages of AFO or LLN based AFO in those with doctor diagnosed CB/E. ‡Becomes short of breath while walking on level ground with healthy people of same age. §Had cough for at least 3 months in the past 12 months. ¶Cough up sputum in the morning for at least 3 months in the past 12 months. **Figures are percentage of different GOLD stages of AFO or LLN based AFO in those with chronic cough and sputum. AFO, air flow obstruction; CB/E, chronic bronchitis/emphysema; FEV1, forced expiratory volume in 1 s; GOLD, Global Initiative for Obstructive Lung Disease; LLN, lower limit of normal. The prevalence of AFO (based on LLN) was higher in rural than urban areas for men (9.2% vs 4.8%, p<0.001) and women (7.7% vs 4.8%, p<0.001). Similar patterns were observed when AFO was based on fixed ratio criterion (GOLD grade 1+), and the overall prevalence was slightly lower compared with LLN (FEV1/FVC) except for those aged >60 years (figure 1, table 3 and see online supplementary table S2). Regardless of the different definitions used, there was a nearly 10-fold variation in the prevalence of AFO across the 10 study regions, with the highest prevalence observed in Sichuan (18.2% vs 18.5%) and lowest in Harbin province (2.5% vs 1.5%) for men and women (figure 1, see online supplementary table S1). Age-adjusted prevalence based on GOLD grade 2+ was lower than LLN (FEV1/FVC) estimates in rural and urban men and women (figure 1, see online supplementary table S3). Similarly, the prevalence of AFO (adjusted for region) increased sharply among smokers particularly after the age of 50 (figure 2 and see online supplementary table S4). The prevalence of AFO among rural men and women increased significantly with age, exposure to wood or coal smoke while cooking, initiation of smoking at a younger age (under 20 years), ex-smokers who stopped smoking due to ill health and BMI <18.5 kg/m2, while AFO decreased with higher annual income and education (table 3, see online supplementary tables S2 and S3).
Figure 1

Prevalence of air flow obstruction (age-adjusted) by sex and region.

Table 3

Age and region standardised prevalence of AFO based on LLN definition, by patient characteristics

CharacteristicsMen
Women
Rural
Urban
Rural
Urban
NPer centNPer centNPer centNPer cent
Overall118 8379.291 2204.8167 7277.7134 7114.8
Age group (%)
 30–3917 2046.212 3612.830 4786.917 6954.7
 40–4932 9326.326 2303.352 7435.640 7074.1
 50–5937 1008.726 5714.652 3717.141 4004.3
 60–6923 54412.917 7666.925 13710.425 2695.9
 70–79805716.882929.6699815.396407.8
 p for trend<0.0001<0.0001<0.0001<0.0001
BMI group (%)
 <18.5682118.0259910.8868012.742597.7
 18.5–2485 0139.550 4825.5107 8327.878 0235.3
 ≥2527 0025.938 1393.451 2146.052 4293.9
p for trend<0.0001<0.0001<0.0001<0.0001
Smoking category (%)
 Never13 4867.816 7963.5158 4017.3128 7164.8
 Occasional13 1237.610 4873.333897.821334.2
 Ex-regular13 9809.713 9135.415617.810836.2
 Current regular78 2489.550 0245.343769.827795.8
 Ever regular92 2289.663 9375.459379.738625.7
p for heterogeneity<0.0001<0.0001<0.0001<0.0001
Pack years*
 <1018 2118.412 3224.2283110.019985.7
 10–1921 3248.816 7864.9157411.09685.1
 >2052 69310.434 8296.0153213.88969.0
p for trend<0.0001<0.00010.24020.1224
Age started smoking (years)
 <2032 03110.521 1596.6208313.684610.1
 20–2435 0219.723 3755.3126814.06435.4
 25–2911 5729.110 0975.07248.94775.2
 ≥3013 6048.393064.518629.918965.2
p for trend<0.0001<0.0001<0.0001<0.0001
Number of cigarettes smoked daily (or equivalent)
 1–466059.329924.617269.69615.5
 5–1425 3769.219 6815.2280511.319825.2
 15–2441 6319.830 5585.5121212.18016.8
 ≥2518 61610.110 7065.81948.91185.5
p for trend0.00190.02270.35530.1128
Reason for stopping among ex-smokers
 Physical illness744213.263868.7100131.84426.7
 Other reason65388.875274.456021.96414.5
p for heterogeneity<0.0001<0.0001<0.00010.0918
Passive smoking†
 No35469.462114.119 7839.021 6434.8
 Yes99407.410 5853.3138 6187.1107 0734.7
p for heterogeneity0.00010.1538<0.00010.3864
Highest education completed
 No formal education15 04312.036068.353 2389.923 2545.5
 Primary school52 10310.017 9835.867 7267.427 3094.8
 Middle/high school49 6217.655 1674.245 6906.371 7724.4
 College/university20707.114 4644.310735.712 3763.9
p for trend<0.0001<0.0001<0.0001<0.0001
Household income (¥)
 2500–499917 02212.924138.425 25610.554615.7
 5000–999927 93910.973196.243 7758.515 5215.4
 10 000–19 99934 3269.225 1845.448 5067.240 8875.2
 ≥20 00039 5506.756 3044.350 1906.172 8424.4
p for trend<0.0001<0.0001<0.0001<0.0001
Currently cooks with coal/wood
 No85 9658.786 4284.731 8727.5122 9504.8
 Yes32 87210.147926.5135 8557.611 7615.5
p for heterogeneity<0.0001<0.0001<0.00010.7517
Ever cooked with coal/wood
 No80 0058.660 5914.612 3817.852 5234.6
 Yes38 83210.030 6295.2155 3467.682 1885.0
p for heterogeneity<0.00010.0014<0.00010.0160

*Restricted to ever regular smokers.

†Among never smokers, exposed to others’ tobacco smoke regularly at home or work.

BMI, body mass index.

Figure 2

Prevalence of air flow obstruction (region-adjusted) by age group.

Age and region standardised prevalence of AFO based on LLN definition, by patient characteristics *Restricted to ever regular smokers. †Among never smokers, exposed to others’ tobacco smoke regularly at home or work. BMI, body mass index. Prevalence of air flow obstruction (age-adjusted) by sex and region. Prevalence of air flow obstruction (region-adjusted) by age group. The prevalence of chronic bronchitis was somewhat greater in rural than in urban areas for men (7.3% vs 6.2%) and women (2.6% vs 1.8%). The prevalence of self-reported physician-diagnosed CB/E was lower and approximately the same in the rural and urban areas for men (3.2% vs 2.9%) and women (2.1% vs 2.4%), among whom less than one-third reported currently taking medication for the condition. Around 80% of rural and 71% of urban men who reported a prior diagnosis of CB/E were regular smokers and also reported chronic cough or breathlessness. In most regions, the prevalence of CB/E was lower than that of AFO diagnosed by spirometry. Of participants with prior physician diagnosis of CB/E, 29.2% and 28.0% had AFO based on LLN and GOLD criteria, respectively (figure 3 and supplementary figure S4). The overall underdiagnosis proportion of AFO was 88.8%, higher in urban than in rural areas (89.4% vs 88.4%) and higher in women compared with men (90.7% vs 86.2%). Similarly, the AFO overdiagnosis proportion was slightly higher in urban than in rural areas (81% vs 62.2%) and higher in women compared with men (73.7% vs 67.7%) (table 4). Of those classified as AFO by spirometry, only 11.2% were correctly diagnosed previously by the physician. The underdiagnosis proportion of AFO was higher in those with lower household income, younger age, having less chronic respiratory symptoms, women, in current regular smokers, but lower in ex-smokers (see online supplementary table S4). There was wide regional variation in the underdiagnosis and overdiagnosis proportion, as well as variation in the treatment for physician-diagnosed CB/E cases (see online supplementary table S1 and figure S5). Sichuan, with the highest prevalence of AFO, had the lowest percentages of overdiagnosed (<40%) AFO. Patterns similar to underdiagnosis were observed for overdiagnosis as well, except it was lower in women. There was also a lack of concordance between self-reported symptom-based chronic bronchitis and spirometry-based AFO (table 3, see online supplementary table S1 and figure 4, see online supplementary figure S6).
Figure 3

Prevalence of air flow obstruction (age-adjusted) by (A) lower limit of normal of forced expiratory ratio versus self-reported doctor diagnosis and (B) self-reported doctor diagnosis with/without current treatment.

Table 4

Age and region-adjusted prevalence, stratified by various baseline variables

CharacteristicsMen (prevalence (%), unless otherwise stated)
Women (prevalence (%) unless otherwise stated)
NCB/EAFOUDODCB/ETNCB/EAFOUDODCB/ET
All210 0573.17.386.267.732.1302 4382.26.390.773.732.7
Sampling regions
 Rural118 8373.29.286.160.534.8167 7272.17.790.364.437.8
 Urban91 2202.94.886.678.028.4134 7112.44.891.583.327.4
Monthly household income (¥)
 2500–499919 4354.110.981.248.036.130 7172.88.485.362.935.8
 5000–999935 2583.58.985.961.833.359 2962.37.190.773.536.1
 10 000–19 99959 5103.07.586.767.431.989 3932.26.390.973.933.2
 ≥20 00095 8543.05.684.571.329.4123 0322.35.389.378.129.0
Highest education completed
 No formal education18 6493.110.485.554.432.176 4922.47.987.562.935.1
 Primary school70 0863.28.184.462.634.595 0352.26.289.772.331.2
 Middle/high school104 7882.86.186.970.928.7117 4622.35.491.878.229.1
 College/university16 5343.75.979.869.521.313 4492.94.971.260.37.5
Smoking status
 Never30 2823.35.983.870.332.2287 1172.15.991.276.231.6
 Occasional23 6103.15.788.175.427.655222.710.290.159.639.5
 Ex-regular27 8935.67.873.961.738.626446.114.777.740.143.4
 Current regular128 2722.57.789.667.727.771552.312.992.959.530.7
Body mass index (kg/m2)
 <18.594206.014.977.545.839.212 9394.410.583.459.936.4
 18.5 to <25135 4952.97.887.166.431.7185 8552.16.791.272.132.7
 ≥2565 1413.04.886.478.328.6103 6432.25.192.080.831.7
Age group (years)
 30–3929 5651.14.796.081.819.748 1731.05.996.880.522.7
 40–4959 1621.45.093.978.921.093 4501.44.994.881.025.0
 50–5963 6712.76.988.671.928.993 7712.45.990.075.832.2
 60–6941 3105.610.379.863.535.250 4063.88.485.568.837.4
 70–7916 3497.513.778.359.141.116 6384.712.086.065.440.7
Respiratory symptoms
None188 3032.16.392.174.624.6277 5101.55.894.677.427.1
Cough or breathlessness19 28710.113.172.559.638.222 7178.511.077.469.238.5
Cough and breathlessness246726.127.654.650.754.4221126.120.553.759.552.6

AFO, air flow obstruction; CB/E, chronic bronchitis and/or emphysema; CB/ET, participants currently under treatment for CB/E; OD, overdiagnosis; UD, underdiagnosis.

Figure 4

Prevalence of age-adjusted (A) chronic cough and phlegm with air flow obstruction (lower limit of normal, LLN), and (B) breathlessness with airflow obstruction (LLN).

Age and region-adjusted prevalence, stratified by various baseline variables AFO, air flow obstruction; CB/E, chronic bronchitis and/or emphysema; CB/ET, participants currently under treatment for CB/E; OD, overdiagnosis; UD, underdiagnosis. Prevalence of air flow obstruction (age-adjusted) by (A) lower limit of normal of forced expiratory ratio versus self-reported doctor diagnosis and (B) self-reported doctor diagnosis with/without current treatment. Prevalence of age-adjusted (A) chronic cough and phlegm with air flow obstruction (lower limit of normal, LLN), and (B) breathlessness with airflow obstruction (LLN). The prevalence of self-reported doctor-diagnosed asthma was <1% among men and women, whereas tuberculosis was marginally greater in urban than in rural areas for men (2.6% vs 1.6%) and women (1.5% vs 0.8%). The prevalence of restrictive abnormality was highest among the ex-regular smokers (men vs women: 29.5% vs 25.1%), men aged 70–79 years (37.5%) and women aged 30–39 years (28.7%; see online supplementary table S5).

Discussion

This is by far the largest population-based study in China of the prevalence and socioeconomic and lifestyle correlates of AFO in adult Chinese men and women. It involved 10 geographically and socioeconomically diverse regions and showed that there is a wide heterogeneity in the prevalence of AFO by region, age, socioeconomic and lifestyle factors such as smoking and BMI. Overall, self-reported prior diagnosis of CB/E was found to be poorly correlated with AFO based on the measured lung function and less than one-third of those with physician diagnosis were receiving treatment at the time of the survey. The estimated underdiagnosis and overdiagnosis proportions were high in rural and urban areas. Several studies from China have estimated COPD prevalence in adult populations, but the results have not been consistent, with the reported prevalence between 3% and 12%.5–7 In our study, the overall weighted prevalence of AFO based on GOLD 1+ definition for ages 40–79 was 6% (ranging from 2% in Harbin to 14% in Sichuan), much lower than that reported by Buist et al7 for China (11.4%) and many other countries such as the USA (19.6%), Australia (19.2%), Turkey (10.1%), Austria (26.1%), Iceland (17.8%) and Poland (22.1%). Although the study by Buist et al7 measured postbronchodilator lung function, the sample sizes were much smaller (473–893 in each country) than ours (>0.5 million) and the majority of them were from one region or city in each of the countries and thus, could not be nationally representative, particularly in a country with large heterogeneity such as China. Despite this, the large difference in the prevalence of AFO between CKB population and previous studies of Western and Chinese populations is likely to be largely real, for the CKB participants were much younger, with only 6.4% aged ≥70 years compared with 10–25% participants in other studies.5 The huge variation in the reported prevalence from different countries and even in different or same regions of a country could be accounted for by several factors, including data acquisition methods, quality control of spirometry measurements, types of sampling population (such as exposure to environmental pollutants, age, previous history of diseases, smoking history and family history, dietary patterns and physical activity) as well as the diagnostic criteria used (eg, GOLD, ERS/ATS criteria used to define COPD).13 14 Our study confirms the previous observations5 of large heterogeneity in the prevalence of AFO across different regions of China, with very high prevalence in the Sichuan region for men and women. We did not compare the nutrient intake and physical activities across different regions in this paper, but hypothesise that it is highly unlikely that lifestyle factors could completely explain the substantial heterogeneity observed across different regions. Most of the rural participants were farmers and there were no major differences in the dietary patterns or smoking habit across different regions. Sichuan, 1 of the 10 regions with the highest prevalence of AFO, was included because of higher mortality rate from COPD reported in our previous studies.15 The study area in Sichuan is situated in a valley and environmental conditions such as temperature inversion could play a role in the prevalence of AFO as it is related to pollution levels. Currently, data on genetic biomarkers for a number of health outcomes, including respiratory health, is being studied in this population that could possibly explain some of the variations in the prevalence of AFO in different regions. The prevalence of asthma in our sampling population was low and similar to previous findings16; lower diagnosed asthma prevalence in China could be due to poor diagnostic facilities making it difficult to differentiate between obstructive lung diseases. As in previous studies,5 we found that men had higher prevalence of AFO than women, probably due to high smoking prevalence in Chinese men. The higher prevalence observed among rural women could be due to greater exposure to environmental pollutants including household air pollution while cooking food using solid fuel, low socioeconomic status or lung infections early in life. In the present study we reported AFO results based on fixed forced expiratory ratio and LLN of forced expiratory ratio so that comparison with previous studies with different diagnostic criteria could be made. The AFO prevalence based on LLN criteria using GLI reference equations was higher than the forced expiratory ratio criteria. This could be due to higher cut-off values for forced expiratory ratio in the Chinese population with age under 60. Previous papers have reported higher false-positive in the elderly population when using the fixed ratio criteria as it lacks specificity, but using the GLI reference equations to some extent overcomes the problem, although it needs to be validated independently.17 18 The extent of underdiagnosis and overdiagnosis of AFO in the present study population is much greater than that reported previously in western countries.19–24 The spirometry-based prevalence of AFO is much greater than self-reported prior physician-diagnosed CB/E. In China, the majority of COPD diagnoses are based on clinical examination and measurement of lung function is not common, particularly, in rural health clinics.25 Our study showed that younger participants, particularly those who are asymptomatic and current smokers and have middle-household income, are relatively more likely to be underdiagnosed. When subgrouped for severity of AFO based on the percent predicted FEV1, the majority of participants had either moderate or severe AFO suggesting that underdiagnosis might be more likely. Validation of this finding would be important as these participants are at a higher risk of developing COPD and early preventive action such as smoking cessation in these groups would be expected to gain the most long-term benefit. Those with a smoking history and presence of respiratory symptoms were more likely to be overdiagnosed for AFO. Similar findings have also been reported in other studies. A recent study in the USA26 found that 42.5% of those diagnosed with COPD were false positive with no airway obstruction, with most of the false-positive diagnosis seen among smokers with presence of respiratory symptoms. New GOLD guidelines recommend that spirometry should be one of the essential criteria for the clinical diagnosis and management of COPD27 28 among those reporting chronic productive cough or sputum production, dyspnoea and exposure to risk factors. Although spirometry is more reproducible and has greater sensitivity and specificity compared with peak expiratory flow, its use is not that frequent in many low-income and middle-income countries, particularly in rural areas.29 The relatively low prevalence of self-reported CB/E in our study could be due to lack of awareness of the problem in the participants and also lack of adequate health facilities in proximity where the participants dwell. Further, recall bias could also not be excluded as a cause of the observed low proportion of diagnosed participants with AFO. In spite of a large sample size and wide geographical locations covered, our study has some limitations. First, we did not administer a bronchodilator as part of the spirometry procedure, and hence no postbronchodilator lung function measurement was carried out. Postbronchodilator forced expiratory ratio lower than LLN or 0.70 is suggested to confirm persistent air flow limitation and thus the presence of COPD in the latest ERS/ATS and GOLD guidelines.28 30 This means the AFO observed in our study could be either COPD or asthma related, therefore the prevalence may be somewhat overestimated. Although postbronchodilator is often used to identify patients with COPD and the course of treatment, its use to differentiate from asthma could be influenced by the day of testing, the baseline lung function before the delivery of testing and also the number of drugs given to test.31 Second, the instrument we used at baseline did not give us the spirogram and thus incomplete exhalation could not be ruled out completely although every effort was made to explain to the participants to blow out as long as possible. A reduction in FVC due to incomplete exhalation could lead to underestimation of AFO and also could be the reason for higher prevalence of restrictive lung disease observed in our population where we used a modified definition, considering that we did not collect total lung capacity data that is usually required to define the restrictive lung disease. Third, we did not collect exacerbation history data at baseline and used GLI predictive equations12 based on the latest predictive equations for north China and southeast Asia where bias due to internal migration from south to the north cannot be completely excluded. Although most of the participants in our study were Han Chinese, some degree of misclassification of grade of AFO as classified by GOLD criteria may have occurred. In summary, this extremely large study provides good evidence about the burden of AFO in adult Chinese men and women. Owing to the lack of use of spirometry for diagnosing AFO in routine clinical practice, a high proportion of such patients were not identified previously. Even among those with prior diagnosis of COPD, two-thirds lacked long-term treatment. Although a number of socioeconomic and lifestyle factors were associated with poor detection and treatment, a large proportion of regional variation remained unexplained. These findings highlight major respiratory health problems in China that need immediate attention to carry out appropriate interventions for optimal disease management as well as to develop the prevention strategies to be implemented in order to improve the current and future respiratory health in the Chinese population.
  27 in total

1.  Cohort profile: the Kadoorie Study of Chronic Disease in China (KSCDC).

Authors:  Zhengming Chen; Liming Lee; Junshi Chen; Rory Collins; Fan Wu; Yu Guo; Pamela Linksted; Richard Peto
Journal:  Int J Epidemiol       Date:  2005-08-30       Impact factor: 7.196

Review 2.  Global burden of COPD: risk factors, prevalence, and future trends.

Authors:  David M Mannino; A Sonia Buist
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

3.  The prevalence of asthma and asthma-like symptoms among adults in rural Beijing, China.

Authors:  M Chan-Yeung; L X Zhan; D H Tu; B Li; G X He; R Kauppinen; M Nieminen; D A Enarson
Journal:  Eur Respir J       Date:  2002-05       Impact factor: 16.671

4.  Prevalence of physician-diagnosed COPD and its association with smoking among urban and rural residents in regional mainland China.

Authors:  Fei Xu; XiaoMei Yin; Min Zhang; HongBing Shen; LinGeng Lu; YaoChu Xu
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

5.  International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study.

Authors:  A Sonia Buist; Mary Ann McBurnie; William M Vollmer; Suzanne Gillespie; Peter Burney; David M Mannino; Ana M B Menezes; Sean D Sullivan; Todd A Lee; Kevin B Weiss; Robert L Jensen; Guy B Marks; Amund Gulsvik; Ewa Nizankowska-Mogilnicka
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

Review 6.  The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what?

Authors:  Jørgen Vestbo; Suzanne S Hurd; Roberto Rodriguez-Roisin
Journal:  Clin Respir J       Date:  2012-10       Impact factor: 2.570

Review 7.  Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations.

Authors:  Peter M A Calverley; Paul Albert; Paul P Walker
Journal:  Lancet Respir Med       Date:  2013-06-18       Impact factor: 30.700

8.  Association of chronic obstructive pulmonary disease with coronary artery disease.

Authors:  Bin-Miao Liang; Zhi-Bo Xu; Qun Yi; Xue-Mei Ou; Yu-Lin Feng
Journal:  Chin Med J (Engl)       Date:  2013       Impact factor: 2.628

9.  Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study.

Authors:  W M Vollmer; Thorn Gíslason; P Burney; P L Enright; A Gulsvik; A Kocabas; A S Buist
Journal:  Eur Respir J       Date:  2009-05-21       Impact factor: 16.671

Review 10.  COPD in China: the burden and importance of proper management.

Authors:  Xiaocong Fang; Xiangdong Wang; Chunxue Bai
Journal:  Chest       Date:  2011-04       Impact factor: 9.410

View more
  13 in total

1.  COPD and its association with smoking in the Mainland China: a cross-sectional analysis of 0.5 million men and women from ten diverse areas.

Authors:  Om P Kurmi; Liming Li; Jenny Wang; Iona Y Millwood; Junshi Chen; Rory Collins; Yu Guo; Zheng Bian; Jiangtao Li; Biyun Chen; Kaixu Xie; Weifan Jia; Yali Gao; Richard Peto; Zhengming Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-20

2.  BMJ Open Respiratory Research: 1 year on.

Authors:  Matt P Wise; Stephen J Chapman
Journal:  BMJ Open Respir Res       Date:  2015-01-22

3.  A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults.

Authors:  Iona Y Millwood; Derrick A Bennett; Robin G Walters; Robert Clarke; Dawn Waterworth; Toby Johnson; Yiping Chen; Ling Yang; Yu Guo; Zheng Bian; Alex Hacker; Astrid Yeo; Sarah Parish; Michael R Hill; Stephanie Chissoe; Richard Peto; Lon Cardon; Rory Collins; Liming Li; Zhengming Chen
Journal:  Int J Epidemiol       Date:  2016-06-14       Impact factor: 7.196

4.  Excess risk of major vascular diseases associated with airflow obstruction: a 9-year prospective study of 0.5 million Chinese adults.

Authors:  Om P Kurmi; Liming Li; Kourtney J Davis; Jenny Wang; Derrick A Bennett; Ka Hung Chan; Ling Yang; Yiping Chen; Yu Guo; Zheng Bian; Junshi Chen; Liuping Wei; Donghui Jin; Rory Collins; Richard Peto; Zhengming Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-03-08

5.  Patterns and management of chronic obstructive pulmonary disease in urban and rural China: a community-based survey of 25 000 adults across 10 regions.

Authors:  Om P Kurmi; Kourtney J Davis; Kin Bong Hubert Lam; Yu Guo; Julien Vaucher; Derrick Bennett; Jenny Wang; Zheng Bian; Huaidong Du; Liming Li; Robert Clarke; Zhengming Chen
Journal:  BMJ Open Respir Res       Date:  2018-02-19

Review 6.  Under- and over-diagnosis of COPD: a global perspective.

Authors:  Terence Ho; Ruth P Cusack; Nagendra Chaudhary; Imran Satia; Om P Kurmi
Journal:  Breathe (Sheff)       Date:  2019-03

7.  Chronic obstructive pulmonary disease in China: a nationwide prevalence study.

Authors:  Liwen Fang; Pei Gao; Heling Bao; Xun Tang; Baohua Wang; Yajing Feng; Shu Cong; Juan Juan; Jing Fan; Ke Lu; Ning Wang; Yonghua Hu; Linhong Wang
Journal:  Lancet Respir Med       Date:  2018-04-09       Impact factor: 30.700

8.  COPD Underdiagnosis and Misdiagnosis in a High-Risk Primary Care Population in Four Latin American Countries. A Key to Enhance Disease Diagnosis: The PUMA Study.

Authors:  Alejandro Casas Herrera; Maria Montes de Oca; Maria Victorina López Varela; Carlos Aguirre; Eduardo Schiavi; José R Jardim
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

9.  Validity of COPD diagnoses reported through nationwide health insurance systems in the People's Republic of China.

Authors:  Om P Kurmi; Julien Vaucher; Dan Xiao; Michael V Holmes; Yu Guo; Kourtney J Davis; Chen Wang; Haiyan Qin; Iain Turnbull; Peng Peng; Zheng Bian; Robert Clarke; Liming Li; Yiping Chen; Zhengming Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-03-01

10.  Do symptom-based questions help screen COPD among Chinese populations?

Authors:  Qun Zhang; Min Wang; Xiaona Li; Hong Wang; Jianming Wang
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.